177. (New) The method of claim 176, wherein said peptide comprises a P at position two, and a L at the carboxyl terminus.

178. (New) The method of claim 176, wherein said peptide comprises a P at position two, and an I at the carboxyl terminus.

179. (New) The method of claim 176, wherein prior to (a), said peptide is expressed by an expression vector comprising a nucleic acid encoding said peptide.

180. (New) The method of claim 176, wherein, prior to (a), said peptide is endogenously processed from a polypeptide selected from the group consisting of:

(a) an oligopeptide less than 15 amino acids in length comprising said peptide;

(b) a fusion protein comprising said peptide;

(c) a homopolymer of said peptide; and

(d) a heteropolymer of said peptide.

181. (New) The method of claim 180, wherein said peptide is endogenously processed from an oligopeptide less than 15 amino acids in length comprising said peptide.

182. (New) The method of claim 180, wherein said peptide is endogenously processed from a fusion protein comprising said peptide.

183. (New) The method of claim 182, wherein said fusion protein comprises said peptide and a spacer.

184. (New) The method of claim 182, wherein said fusion protein comprises said peptide and a T helper peptide.

185. (New) The method of claim 180, wherein said peptide is endogenously processed from a homopolymer of said peptide.

72

186. (New) The method of claim 180, wherein said peptide is endogenously processed from a heteropolymer of said peptide.

187. (New) The method of claim 181, wherein said oligopeptide is expressed by an expression vector comprising a nucleic acid encoding said oligopeptide.

188. (New) The method of claim 182, wherein said fusion protein is expressed by an expression vector comprising a nucleic acid encoding said fusion protein.

189. (New) The method of claim 185, wherein said homopolymer is expressed by an expression vector comprising a nucleic acid encoding said homopolymer.

190. (New) The method of claim 186, wherein said heteropolymer is expressed by an expression vector comprising a nucleic acid encoding said heteropolymer.

191. (New) The method of claim 176, further comprising evaluating said peptide for an ability to serve as a target for HLA-B7 restricted cytotoxic T lymphocytes (CTLs).

192. (New) The method of claim 176, further comprising evaluating said peptide for an ability to induce an HLA-B7 restricted CTL response *in vitro*.

193. (New) The method of claim 176, further comprising evaluating said peptide for an ability to induce an HLA-B7 restricted CTL response *in vivo*.

92

194. (New) The method of claim 176, further comprising eliciting an HLA-B7 restricted CTL response in a patient.

195. (New) The method of claim 176, further comprising eliciting an HLA-B7 restricted CTL response in CTL precursors from a patient.

196. (New) The method of claim 176, which comprises a diagnostic method.

197. (New) The method of claim 176, which comprises a prognostic method.

198. (New) The method of claim 176, which comprises administering a vaccine composition comprising said peptide.

199. (New) The method of claim 176, wherein said contacting is performed in an individual human.

200. (New) The method of claim 176, wherein said contacting is performed in a population of humans.

201. (New) The method of claims 178, wherein said epitope is selected from the group consisting of: LPENNVLSPL, APAPAPSWPL, SPALNKMFCQL, RPILTIITL, LPPGSTKRAL, SPQPKKKPL, and KPLDGEYFTL.

202. (New) The method of claim 201, wherein said epitope is LPENNVLSPL.

203. (New) The method of claim 201, wherein said epitope is APAPAPSWPL.

204. (New) The method of claim 201, wherein said epitope is SPALNKMFCQL.

205. (New) The method of claim 201, wherein said epitope is RPILTIITL.

206. (New) The method of claim 201, wherein said epitope is LPPGSTKRAL.

207. (New) The method of claim 201, wherein said epitope is SPQPKKKPL.

208. (New) The method of claim 201, wherein said epitope is KPLDGEYFTL.

209. (New) A method of binding a human leukocyte antigen (HLA)-B7 molecule with a peptide comprising an epitope of p53, comprising:

(a) contacting said HLA-B7 molecule with a peptide comprising an epitope selected from the group consisting of: GTRVRAMAI and GSRAHSSHL; wherein said peptide is 8-11 amino acids in length; and thereby

(b) binding said HLA-B7 molecule and said peptide.

210. (New) The method of claim 209, wherein prior to (a), said peptide is expressed by an expression vector comprising a nucleic acid encoding said peptide.

211. (New) The method of claim 209, wherein, prior to (a), said peptide is endogenously processed from a polypeptide selected from the group consisting of:

(a) an oligopeptide less than 15 amino acids in length comprising said peptide;

(b) a fusion protein comprising said peptide;

(c) a homopolymer of said peptide; and

(d) a heteropolymer of said peptide.

212. (New) The method of claim 211, wherein said peptide is endogenously processed from an oligopeptide less than 15 amino acids in length comprising said peptide.

213. (New) The method of claim 211, wherein said peptide is endogenously processed from a fusion protein comprising said peptide.

214. (New) The method of claim 213, wherein said fusion protein comprises said peptide and a spacer.

215. (New) The method of claim 213, wherein said fusion protein comprises said peptide and a T helper peptide.

216. (New) The method of claim 211, wherein said peptide is endogenously processed from a homopolymer of said peptide.

217. (New) The method of claim 211, wherein said peptide is endogenously processed from a heteropolymer of said peptide.

218. (New) The method of claim 212, wherein said oligopeptide is expressed by an expression vector comprising a nucleic acid encoding said oligopeptide.

219. (New) The method of claim 213, wherein said fusion protein is expressed by an expression vector comprising a nucleic acid encoding said fusion protein.

220. (New) The method of claim 216, wherein said homopolymer is expressed by an expression vector comprising a nucleic acid encoding said homopolymer.

221. (New) The method of claim 217, wherein said heteropolymer is expressed by an expression vector comprising a nucleic acid encoding said heteropolymer.

222. (New) The method of claim 209, further comprising evaluating said peptide for an ability to serve as a target for HLA-B7 restricted cytotoxic T lymphocytes (CTLs).

223. (New) The method of claim 209, further comprising evaluating said peptide for an ability to induce an HLA-B7 restricted CTL response *in vitro*.

72

224. (New) The method of claim 209, further comprising evaluating said peptide for an ability to induce an HLA-B7 restricted CTL response *in vivo*.

225. (New) The method of claim 209, further comprising eliciting an HLA-B7 restricted CTL response in a patient.

226. (New) The method of claim 209, further comprising eliciting an HLA-B7 restricted CTL response in CTL precursors from a patient.

227. (New) The method of claim 209, which comprises a diagnostic method.

228. (New) The method of claim 209, which comprises a prognostic method.

229. (New) The method of claim 209, which comprises administering a vaccine composition comprising said peptide.

230. (New) The method of claim 209, wherein said contacting is performed in an individual human.

231. (New) The method of claim 209, wherein said contacting is performed in a population of humans.

232. (New) The method of claim 209, wherein said epitope is GTRVRAMAI.

233. (New) The method of claim 209, wherein said epitope is GSRAHSSHL.